# Endocrine Agents - Diabetes – Insulin  

|||
| ---------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Criteria 1 | NP Agents- Admelog, Basaglar, Fiasp, Humalog U-200, Humulin N U-100, Humulin R U-100, Insulin Degludec (Tresiba is P, ST, BvG), Insulin Glargine (Lantus is P, BvG), Lyumjev, Novolin 70-30, Novolin N U-100, Novolin R U-100, Semglee, Rezvoglar, Basaglar Tempo Pen, Humalog U-100 Tempo Pen, Lyumjev Tempo Pen |
| Criteria 2 | NP Agents- Inhaled Insulin-  Afrezza                                                                                                                                                                                                                                                                              |
| Criteria 3 | Tresiba (P, ST, BvG)                                                                                                                                                                                                                                                                                              |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Endocrine Agents: Diabetes – Insulin</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred Products</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>ADMELOG</td>
<td>027413</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ADMELOG</td>
<td>034731</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>BASAGLAR</td>
<td>062867</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FIASP</td>
<td>077136</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FIASP</td>
<td>077137</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FIASP</td>
<td>077138</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>HUMALOG U-200</td>
<td>073403</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>HUMULIN N U-100</td>
<td>001740</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>HUMULIN N U-100</td>
<td>051292</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>HUMULIN R U-100</td>
<td>029916</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>HUMULIN R U-100</td>
<td>075447</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>INSULIN DEGLUDEC</td>
<td>071842</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>INSULIN DEGLUDEC</td>
<td>071843</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>INSULIN DEGLUDEC</td>
<td>079385</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>INSULIN GLARGINE</td>
<td>047780</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>INSULIN GLARGINE</td>
<td>062867</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>LYUMJEV</td>
<td>081183</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>LYUMJEV</td>
<td>081186</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>LYUMJEV</td>
<td>081187</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NOVOLIN 70-30</td>
<td>016311</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NOVOLIN 70-30</td>
<td>058952</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NOVOLIN N U-100</td>
<td>001740</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NOVOLIN N U-100</td>
<td>051292</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>NOVOLIN R U-100</td>
<td>001723</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>NOVOLIN R U-100</td>
<td>049833</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SEMGLEE</td>
<td>082542</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SEMGLEE</td>
<td>082541</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SEMGLEE</td>
<td>062867</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SEMGLEE</td>
<td>047780</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>REZVOGLAR</td>
<td>082926</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>HUMALOG TEMPO</td>
<td>034731</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>BASAGLAR TEMPO</td>
<td>062867</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>LYUMJEV TEMPO</td>
<td>081186</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">120 days</span> with at least <span class="underline">two preferred</span> drugs having a similar duration of action?</p>
<p>If yes, please submit the medication trials and dates.</p>
<p>Please note: An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen with documented adherence and appropriate dose escalation. </p></td>
<td>Y </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1002 </td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td>Does the patient have a condition that is difficult to control (i.e., prone to ketoacidosis, hypoglycemia)?</td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1005</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1004</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1005</td>
<td></td>
<td>Select  </td>
<td>Is the request for generic insulin glargine, generic insulin glargine-yfgn, brand Semglee, or generic insulin degludec? </td>
<td>Y  </td>
<td>1006</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1008 </td>
</tr>
<tr class="odd">
<td>9</td>
<td>1006</td>
<td></td>
<td>Select</td>
<td>What medication is being requested?</td>
<td>Generic insulin glargine</td>
<td>1007</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Generic insulin glargine-yfgn</td>
<td>1007</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Brand Semglee</td>
<td>END (Approve x 365 Days) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Generic insulin degludec</td>
<td>1007</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1235</td>
</tr>
<tr class="even">
<td>10</td>
<td>1007</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the brand medication been attempted and failed or is the brand medication contraindicated?    </p>
<p>If yes, please submit documentation.</p></td>
<td>Y  </td>
<td> END (Approve x 365 Days) </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235 </td>
</tr>
<tr class="even">
<td>11</td>
<td>1008</td>
<td></td>
<td>Select</td>
<td>Is the request for any of the following: Basaglar Tempo Pen, Humalog Tempo Pen, or Lyumjev Tempo Pen?</td>
<td>Y</td>
<td>1009</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="even">
<td>12</td>
<td>1009</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response or documentation submitted to support medical necessity beyond convenience for why the patient cannot use the corresponding FlexPens or Kwikpens?</p>
<p>If yes, please submit documentation.</p></td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>13</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td> Y    </td>
<td> END (Approve x 365 Days) </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="even">
<td>14</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days 

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Endocrine Agents: Diabetes – Insulin</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Afrezza</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>AFREZZA</td>
<td>073242</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>AFREZZA</td>
<td>073243</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AFREZZA</td>
<td>073246</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>AFREZZA</td>
<td>074308</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AFREZZA</td>
<td>076973</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>AFREZZA</td>
<td>079460</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">120 days</span> with at least <span class="underline">two preferred</span> drugs having a similar duration of action?</p>
<p>If yes, please submit the medication trials and dates.</p>
<p>Please note: An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen with documented adherence and appropriate dose escalation.  </p></td>
<td>Y </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1002</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td>Does the patient have a condition that is difficult to control (i.e., prone to ketoacidosis, hypoglycemia)?</td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1005</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1004</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1005</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s spirometry testing prior to initiation with a predicted FEV1 greater than or equal to 70 percent?</p>
<p>If yes, please submit documentation.</p></td>
<td>Y  </td>
<td>1006</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>9</td>
<td>1006</td>
<td></td>
<td>Select</td>
<td>Does the patient have Asthma or Chronic Obstructive Pulmonary Disease (COPD)?</td>
<td>Y</td>
<td>1235</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1007</td>
</tr>
<tr class="odd">
<td>10</td>
<td>1007</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient being nicotine-free for at least 180 days? </p>
<p>If yes, please submit documentation.</p></td>
<td>Y  </td>
<td> END (Approve x 365 Days) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>11</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td> Y    </td>
<td> END (Approve x 365 Days) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>12</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days 

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |

 

 

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Endocrine Agents: Diabetes – Insulin</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Step Therapy Products</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>TRESIBA</td>
<td>071842</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TRESIBA</td>
<td>071843</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>TRESIBA</td>
<td>079385</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">120 days</span> with at least <span class="underline">one preferred</span> drug having a similar duration of action?</p>
<p>If yes, please submit the medication trials and dates.</p>
<p>Please note: An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen with documented adherence and appropriate dose escalation.</p></td>
<td>Y </td>
<td> END (Approve x 365 Days) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y</td>
<td>END (Approve x 365 Days) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1002</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td>Does the patient have a condition that is difficult to control (i.e., prone to ketoacidosis, hypoglycemia)?</td>
<td>Y</td>
<td>END (Approve x 365 Days) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td> Y    </td>
<td> END (Approve x 365 Days) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>7</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days 

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |
